Healthcare & Medical Devices Global On demand · 24-48h

Global Medical Radioactive Microspheres Market Strategic Research Report

Global Medical Radioactive Microspheres Market Strategic Res…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Medical Radioactive Microspheres Market
$2082025
11.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Holmium-166 Microspheres, Yttrium-90 Microspheres

By Application: Cancer Treatment, Diagnosis, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: New Radiomedicine Technology, Grand Pharmaceutical Group Limited, YH Nu-Med, Boston Scientific, Sirtex Medical Limited, Terumo, ABK Biomedical, AtomVie, BWXT Medical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 103 pages
Market size 2025
$208
Million USD
Forecast CAGR
11.6%
2025-2032
Forecast 2032
$448.4
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Medical Radioactive Microspheres market size is predicted to grow from US$ 208 million in 2025 to US$ 444 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

Medical radioactive microspheres are a type of radioactive embolic agent that uses interventional means to inject micron-sized particles (usually 20-45 microns in diameter) containing radionuclides (such as yttrium [90Y]) into the tumor's blood supply artery. The carrier material is mostly ceramic, resin or glass. It releases beta rays through targeted tumors (to kill tumor cells at close range, and at the same time has the function of embolizing blood vessels, which can significantly improve the local control rate of tumors and reduce normal tissue damage. It is mainly used clinically for the treatment of solid tumors such as primary liver cancer and colorectal cancer liver metastasis that cannot be surgically removed. It has the advantages of high targeting, few side effects, and reliable efficacy, and can meet individualized treatment needs through customized personalized activity.

Future development trends, driving factors and obstacles of medical radioactive microspheres

Application field expansion

At present, medical radioactive microspheres are mainly used for liver cancer treatment, but in the future they are expected to be expanded to the treatment of other malignant tumors such as pancreatic cancer, bladder cancer, head and neck cancer, etc. In addition, with the advancement of technology, radioactive microspheres may play a greater role in the treatment of benign diseases.

Technological innovation and product upgrade

The preparation technology of radioactive microspheres will continue to be optimized, such as developing microspheres with smaller particle size and more uniform distribution to improve the treatment effect and reduce side effects. At the same time, the research on visual microspheres will promote the development of real-time monitoring technology, enabling doctors to control the distribution and dosage of microspheres more accurately.

Intensified market competition

As market demand grows, more and more companies will enter the field of medical radioactive microspheres, and market competition will become more intense. At present, major global manufacturers include Sirtex Medical and Boston Scientific Corporation, and more new players may emerge in the future.

Development drivers

Increasing cancer incidenc

The global cancer incidence rate is increasing year by year, especially malignant tumors such as liver cancer. According to the World Health Organization, liver cancer is the sixth most common cancer in the world and the third leading cause of cancer death. As an effective local treatment method, the market demand for radioactive microspheres will continue to grow.

Technological progress

The preparation technology and application technology of radioactive microspheres are constantly improving. For example, the research and application of yttrium [90Y] microspheres make treatment more accurate and safe. In addition, the research on visualized microspheres will further improve the controllability and effect of treatment.

Policy support

Governments of various countries have continuously increased their support for medical technology, especially in the field of cancer treatment. For example, China has introduced a series of policies to support the development of biopharmaceuticals and traditional Chinese medicine industries, and promote the industrialization of technologies such as sustained-release preparations and targeted preparations.

Development obstacles

Technical barriers

The preparation technology of medical radioactive microspheres is complex and requires high-precision equipment and processes. At present, domestic companies still have a certain gap in microsphere preparation technology, relying on imported materials and equipment, which increases production costs and supply chain uncertainty.

Market competition and price pressure

With the intensification of market competition, price pressure will increase. How to reduce production costs and improve market competitiveness while ensuring product quality and efficacy is a challenge faced by companies.

Regulation and approval

As medical devices, medical radioactive microspheres need to undergo strict supervision and approval. Different regulatory requirements in different countries and regions increase the difficulty and time cost of bringing products to market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Medical Radioactive Microspheres market?

What factors are driving Medical Radioactive Microspheres market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Medical Radioactive Microspheres market opportunities vary by end market size?

How does Medical Radioactive Microspheres break out by Type, by Application?

This report presents a comprehensive overview of the global Medical Radioactive Microspheres market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Holmium-166 Microspheres
  • Yttrium-90 Microspheres

Segment by Application

  • Cancer Treatment
  • Diagnosis
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Medical Radioactive Microspheres market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Cancer Treatment, Diagnosis, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Medical Radioactive Microspheres Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 11.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$208
2025
Forecast
$448.4
2032
CAGR
11.6%
2025–2032
Regions
5
global
Key companies
New Radiomedicine TechnologyGrand Pharmaceutical Group LimitedYH Nu-MedBoston ScientificSirtex Medical LimitedTerumoABK BiomedicalAtomVie
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Holmium-166 MicrospheresYttrium-90 Microspheres
By Application
Cancer TreatmentDiagnosisOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Holmium-166 Microspheres
  • 3.1.3 Yttrium-90 Microspheres
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Cancer Treatment
  • 4.1.3 Diagnosis
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 New Radiomedicine Technology
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Grand Pharmaceutical Group Limited
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 YH Nu-Med
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Boston Scientific
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Sirtex Medical Limited
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Terumo
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 ABK Biomedical
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 AtomVie
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 BWXT Medical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Medical Radioactive Microspheres market?
The global Medical Radioactive Microspheres market is estimated at US$ 208 million in 2025 (base year) and is projected to reach US$ 444 million by 2032.
How fast is the Medical Radioactive Microspheres market expected to grow?
The market is expected to grow at a CAGR of 11.6% from 2026 to 2032, expanding from US$ 208 million in 2025 to US$ 444 million in 2032, roughly 2.1 times its base-year value.
What does the Medical Radioactive Microspheres market cover?
Medical radioactive microspheres are a type of radioactive embolic agent that uses interventional means to inject micron-sized particles (usually 20-45 microns in diameter) containing radionuclides (such as yttrium [90Y]) into the tumor's blood supply artery. The carrier material is mostly ceramic, resin or glass.
What are the main segments of the Medical Radioactive Microspheres market by type?
By type, the market is segmented into Holmium-166 Microspheres and Yttrium-90 Microspheres.
Which applications drive demand in the Medical Radioactive Microspheres market?
Key applications covered include Cancer Treatment, Diagnosis and Others.
Who are the key players in the Medical Radioactive Microspheres market?
Key players profiled include New Radiomedicine Technology, Grand Pharmaceutical Group Limited, YH Nu-Med, Boston Scientific, Sirtex Medical Limited, Terumo, ABK Biomedical and AtomVie, among 9 companies covered in total.
Which regions and countries are covered for Medical Radioactive Microspheres?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Medical Radioactive Microspheres market?
Future development trends, driving factors and obstacles of medical radioactive microspheres
What challenges does the Medical Radioactive Microspheres market face?
How to reduce production costs and improve market competitiveness while ensuring product quality and efficacy is a challenge faced by companies.
Who should buy the Medical Radioactive Microspheres market report?
The report is intended for manufacturers and solution providers, distributors and end users in Cancer Treatment, Diagnosis and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Medical Radioactive Microspheres market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.